When One Patient Becomes the Entire Trial

What N=1 Trials Are Teaching Us About the Future of Drug Development

Most of us entered clinical research with a fairly common understanding of what a clinical trial looks like. It typically involves hundreds of patients, numerous sites, years of enrollment, complex statistical plans, data monitoring committees, interim analyses, and large datasets designed to answer a very specific scientific question. The entire system was built around the idea that the more patients we study, the more confident we become in our conclusions.

For decades, that approach has served medicine remarkably well. However, every now and then, our industry faces a challenging a situation that forces us to ask a difficult question: what happens when there is only one patient? Not one patient enrolled in a larger study, not one patient among hundreds, but one patient, one disease, one mutation, and one opportunity to intervene. And suddenly, the traditional framework we’ve relied on for generations begins to look very different.

This is the world of N=1 clinical trials and I believe they may represent one of the most fascinating shifts occurring in modern drug development.

The Patient Who Doesn’t Fit Into Traditional Research

Many diseases that have garnered interest in N=1 approaches are extraordinarily rare. Not rare in the sense of affecting thousands of patients worldwide, but rare in the sense that there may only be a handful of known cases, sometimes even fewer. Occasionally, there may only be one known case.

These patients often have unique genetic alterations, ultra-rare disorders, or molecular abnormalities that simply don’t lend themselves to conventional clinical development. Traditional drug development was never designed to address these situations. 

How do you conduct a randomized study when there are only three known patients on the planet? How do you establish control groups? How do you power statistical analyses? For years, the answer was often simple and unfortunate: we couldn’t. As a result, many patients with ultra-rare diseases had little hope of ever seeing therapies specifically developed for their condition. Today, that's beginning to change.

Precision Medicine Is Driving Us Toward Precision Trials

The rise of genomics has fundamentally altered how we think about disease. We’ve become increasingly skilled at identifying the exact molecular drivers behind a patient’s condition. In some cases, we can pinpoint a single pathogenic mutation responsible for devastating disease. Once you identify the cause, a natural question arises: Can we develop a therapy specifically tailored for that patient?

Advances in gene therapy, gene editing, antisense oligonucleotides, RNA-based therapeutics, and cellular therapies are making that question more realistic than ever before. The science is moving rapidly toward personalized medicine, and the clinical trial model is now trying to catch up. This is where N=1 trials come into play.

These studies challenge one of the foundational assumptions of clinical research, which is, that meaningful evidence must come from large populations. Instead, they ask whether deep understanding of an individual patient’s biology can sometimes provide sufficient evidence to justify intervention. This represents a significant shift in our thinking.

The Statistics Are the Easy Part

One of the common criticisms of N=1 trials is that they lack statistical power. While this is true, I believe the most challenging aspect is often not statistical but ethical. 

Consider a scenario where a child has a rapidly progressive neurodegenerative disease with no available treatment. How much evidence should we require before intervention? When the alternative is certain decline, how should we weigh uncertainty against inaction? How much risk is acceptable when the natural history of the disease itself is catastrophic? 

These aren’t purely scientific questions. Instead they’re human questions that require a different type of decision-making than many of us were trained to perform.

Throughout my career, I’ve worked within highly structured clinical development programs where decisions are guided by predefined rules, statistical boundaries, and established regulatory pathways.

In contrast, N=1 development often operates in a very different environment. The data may be incomplete, the precedent may not exist, the timeline may be compressed, and the patient may not have years available while we wait for perfect evidence. This reality forces all of us, including physicians, sponsors, regulators, and medical monitors, to think differently.

Medical Monitoring Looks Different When There Is Only One Patient

One aspect of N=1 development that fascinates me is how dramatically it changes the role of medical oversight. 

In traditional trials, safety monitoring often focuses on identifying patterns across populations. We’re looking for trends, signals, consistency, and emerging relationships across multiple participants. 

However, in an N=1 setting, since there is only one individual, this requires a shift in perspective. Every laboratory value, every symptom, and every clinical observation holds immense significance. There are no averages to hide behind, no subgroup analyses, and no safety database containing hundreds of comparable patients. Instead, the patient’s unique experience becomes the sole dataset. 

That level of scrutiny requires a different mindset. It demands close collaboration among investigators, treating physicians, sponsors, manufacturing teams, regulatory agencies, and medical monitors.

Consequently, the decisions become highly individualized because the therapy itself is highly individualized. In many ways, it takes clinical development back to its most fundamental purpose: helping a patient sitting in front of us.

Manufacturing May Become the Real Bottleneck

Scientific breakthroughs often dominate headlines, overshadowing the operational realities that ultimately determine whether N=1 therapies become scalable. Creating a personalized therapy is not simply a scientific experimentation. It requires manufacturing infrastructure capable of designing, producing, testing, releasing, and delivering a product for a single individual. 

That is extraordinarily complex, because this requires stringent quality control, regulatory oversight, and patient safety measures. However, the timelines are often compressed because the patient may not be able to wait. This creates challenges that our industry is still learning how to navigate.

As personalized medicines become more sophisticated, manufacturing may become just as important as the underlying biology, if not more important.

What N=1 Trials May Teach the Rest of Us

Even if most clinical research never becomes individualized, N=1 studies are forcing us to rethink some long-held assumptions. They remind us that medicine is ultimately about people, not populations. Populations help us understand disease, while patients are the reason we study it.

For years, drug development has focused on moving from broad populations toward increasingly defined subgroups. N=1 trials represent the culmination of this journey, where the subgroup eventually becomes the individual.

Whether this approach remains limited to ultra-rare diseases or expands into other areas remains to be seen. How personalized can medicine become? How personalized should it become? And what does evidence look like when one patient is all you have? These questions being explored today will likely influence drug development for decades.

Final Thoughts

I don’t believe N=1 trials will replace traditional clinical development, nor should they. Large, well-designed studies remain the cornerstone of evidence-based medicine. However, I do believe N=1 trials represent something important. They demonstrate that innovation in drug development is no longer occurring solely at the level of the therapy itself, but also extends to the clinical trial level. The rules, frameworks, and our understanding of what is possible are all evolving.

As precision medicine continues to advance, we may find ourselves entering an era where the most important clinical trial is not necessarily the largest one. Sometimes, it may be the one designed for a single patient whose disease taught us something entirely new. In this context, N=1 trials may be less about statistics and more about the future of medicine itself.